Healthcare >> Analyst Interviews >> June 2, 2002

Emerging Biotechnology Companies:mark Monane – Needham & Co

DR. MARK MONANE is Principal, Equity Research at Needham and Company, a full-service investment bank in New York City, where he serves as a Senior Analyst in biotechnology and biopharmaceuticals. His coverage universe focuses on small to mid-cap companies in the cardiovascular and cancer areas. Dr. Monane was recently ranked number two in biotechnology in the 2002 Best on the Street Analysts Survey conducted by The Wall Street Journal. Dr. Monane was a full-time faculty member and researcher at Harvard Medical School from 1991 to 1996, reaching the title of Assistant Professor of Medicine. He worked at Merck- Medco Managed Care, LLC, as Director and then Senior Director of Geriatrics from 1996 to 2000. Dr. Monane's research on medication use and geriatrics has resulted in more than 50 original articles and review publications in journals such as Journal of the American Medical Association, Archives of Internal Medicine, Journal of the American Geriatrics Society, Hypertension, and Clinical Pharmacology and Therapeutics. Dr. Monane holds an AB degree from Columbia University, an MD from New York University School of Medicine, an MS degree from Harvard School of Public Health, and an MBA degree from Columbia Business School. He completed postdoctoral training in primary care internal medicine at Montefiore Hospital, geriatric medicine at Harvard Medical School, and geriatric clinical pharmacology at Harvard Medical School. He is board certified in internal medicine, geriatric medicine, clinical pharmacology, and utilization review/quality assurance. He is currently an Adjunct Associate Clinical Professor at Rutgers College of Pharmacy in New Jersey. He serves on the Board of Directors for the American Federation for Aging Research and the American Society of Consultant Pharmacists. Profile
TWST: Would you begin by telling us about the focus of your coverage at

Needham & Company?

Dr. Monane: Our coverage is focused on companies addressing large areas

of unmet needs in